Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: Long-Term Changes of Clinical Severity and Laboratory Parameters.
10.4168/aair.2016.8.4.375
- Author:
Dong Ho NAHM
1
;
Areum AHN
;
Myoung Eun KIM
;
Su Mi CHO
;
Mi Jung PARK
Author Information
1. Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea. dhnahm@gmail.com
- Publication Type:Brief Communication
- Keywords:
Dermatitis, atopic;
immunoglobulins;
immunomodulation;
therapy;
antibodies;
immunoglobulin G
- MeSH:
Adult;
Antibodies;
Antibodies, Anti-Idiotypic;
Dermatitis, Atopic*;
Eosinophils;
Follow-Up Studies;
Humans;
Immunization, Passive*;
Immunoglobulin E;
Immunoglobulin G;
Immunoglobulins*;
Immunomodulation;
Injections, Intramuscular
- From:Allergy, Asthma & Immunology Research
2016;8(4):375-382
- CountryRepublic of Korea
- Language:English
-
Abstract:
This report evaluated long-term changes in clinical severity and laboratory parameters in 3 adult patients with severe recalcitrant atopic dermatitis (AD) who were treated with intramuscular injections of 50 mg of autologous immunoglobulin G (IgG) twice a week for 4 weeks (autologous immunoglobulin therapy, AIGT) and followed up for more than 2 years after the treatment. We observed the following 4 major findings in these 3 patients during the long-term follow-up after AIGT. (1) Two of the 3 patients showed a long-term clinical improvement for more than 36 weeks after AIGT with a maximum decrease in clinical severity score greater than 80% from baseline. (2) These 2 patients also showed long-term decreases in serum total IgE concentrations and peripheral blood eosinophil count for more than 36 weeks after AIGT with a maximum decrease in the two laboratory parameters of allergic inflammatory greater than 70% from baseline. (3) No significant side effect was observed during the 2 years of follow-up period after the AIGT in all 3 patients. (4) Serum levels of IgG anti-idiotype antibodies to the F(ab')2 fragment of autologous IgG administered for the treatment were not significantly changed after AIGT in all 3 patients. These findings suggest that AIGT has long-term favorable effects on both clinical severity and laboratory parameters in selected patients with severe recalcitrant AD. Further studies are required to evaluate the clinical usefulness and therapeutic mechanism of AIGT for AD.
